News

Edwards, SAPIEN 3 trial, mortality, EuroPCR 2015

Edwards Lifesciences Corp. announced that 30-day outcomes for intermediate-risk patients treated transfemorally with the SAPIEN 3 transcatheter aortic valve demonstrated very low mortality and...

St. Jude Medical, OCT, PCI, ILUMIEN, EuroPCR 2015

St. Jude Medical Inc. announced preliminary results from the ILUMIEN I trial and final results from the ILUMIEN II clinical study. Taken together, the findings from both studies show that with...

virtual heart, virtual organs, virtual clinical testing

The cost of bringing innovative new cardiovascular technology to the U.S. market today is staggering, numbering in the tens of millions up to $1 billion. Many in the medical device and drug...

Visipaque, IOCM, LOCM, angioplasty, EuroPCR 2015

Significantly fewer renal and cardiac events are associated with angioplasty procedures using isosmolar contrast medium (IOCM) agent Visipaque (iodixanol) than those using low-osmolar contrast...

Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results

Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system, with no new major adverse...

IN.PACT Admiral, Global Study, DEB SFA-LONG, long peripheral lesions, EuroPCR

New clinical data from two different studies show the IN.PACT Admiral drug-coated balloon from Medtronic plc successfully treated long lesions in the superficial femoral and popliteal arteries....

St. Jude Medical, FFR, cFFR, CONTRAST, DEFER, study, EuroPCR 2015

St. Jude Medical Inc. announced new results from two clinical studies further supporting the use of its fractional flow reserve (FFR) technology to optimize percutaneous coronary intervention...

Direct Flow Medical, Transcatheter Aortic Valve System, DISCOVER, EuroPCR

Direct Flow Medical Inc. announced positive two-year data from the DISCOVER CE Mark Trial studying its Direct Flow Medical Transcatheter Aortic Valve System at the EuroPCR conference in...

The Phase C results of the ProMRI Clinical Study were presented at the late-breaking clinical trial session of the Heart Rhythm Society (HRS) 2015 meeting. 

cardiomems, st. jude medical, heart failure

Important new data presented during the Heart Rhythm Society's (HRS) 36th annual Scientific Session supporting improved outcomes and cost-effectiveness of the CardioMEMS HF System for the...

rivaroxaban, Xarelto, VENTURE-AF, VKA, atrial fibrillation, Heart Rhythm 2015

Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from the VENTURE-AF trial. The study explored the potential of once-daily Xarelto (rivaroxaban) as...

Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation Fortitude sirolimus-eluting bioresorbable scaffold (BRS) at EuroPCR 2015. Juan...

Micra TPS, Transcatheter Pacing Study, Heart Rhythm 2015, Medtronic

The first-in-human trial of a new miniaturized leadless pacemaker implanted directly inside the heart found the Medtronic Micra transcatheter pacing system (TPS) safe and effective in patients...

Clinical trial results showed that full-body magnetic resonance imaging (MRI) scans do not affect the Medtronic Evera MRI SureScan implantable cardioverter defibrillator’s (ICD) ability to detect...

CT-FFR, Heartflow Analysis, coronary artery disease, EuroPCR, RIPCORD

Adding the HeartFlow FFRCT Analysis to a standard coronary computed tomography angiogram (cCTA) may change the course of treatment in more than one-third of patients with...

botox, atrial fibrillation, cardiac surgery, HRS

A study presented at Heart Rhythm 2015 found that botulinum toxin (botox) injections into epicardial fat pads during coronary artery bypass graft (CABG) surgery can be beneficial for the patient....

St. Jude Medical, Merlin, remote monitoring, lower costs, hospitalizations, HRS

New data from St. Jude Medical found that patients with cardiac devices who use remote monitoring have significantly fewer hospitalizations and lower overall healthcare costs than patients who do...

antiplatelet medication, prasugrel, clopidogrel, risk algorithm, SCAI

A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive...

safe exercise level, atrial fibrillation, AF, men, women, HRS

New research reports significant differences between men and women with atrial fibrillation (AF) and the safety of intense physical activity. The study found that both moderate and vigorous levels...

cilostazol, DAPT, bridge therapy, surgery, bleeding risk, SCAI

Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug cilostazol prior to a surgical procedure safely transitioned off of dual antiplatelet therapy (...